Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

ALK positively regulates MYCN activity through repression of HBP1 expression

Claeys, Shana ; Denecker, Geertrui ; Durinck, Kaat ; Decaesteker, Bieke ; Mus, Liselot M. ; Loontiens, Siebe ; Vanhauwaert, Suzanne ; Althoff, Kristina ; Wigerup, Caroline LU and Bexell, Daniel LU , et al. (2019) In Oncogene 38(15). p.2690-2705
Abstract

ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the ‘HMG-box transcription factor 1’ (HBP1) through the PI3K-AKT–FOXO3a signaling axis. HBP1 inhibits both the transcriptional activating and repressing activity of MYCN, the latter being mediated through PRC2 activity.... (More)

ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the ‘HMG-box transcription factor 1’ (HBP1) through the PI3K-AKT–FOXO3a signaling axis. HBP1 inhibits both the transcriptional activating and repressing activity of MYCN, the latter being mediated through PRC2 activity. HBP1 itself is under negative control of MYCN through miR-17~92. Combined targeting of HBP1 by PI3K antagonists and MYCN signaling by BET- or HDAC-inhibitors blocks MYCN activity and significantly reduces tumor growth, suggesting a novel targeted therapy option for high-risk neuroblastoma.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Oncogene
volume
38
issue
15
pages
2690 - 2705
publisher
Nature Publishing Group
external identifiers
  • scopus:85058246022
  • pmid:30538293
ISSN
0950-9232
DOI
10.1038/s41388-018-0595-3
language
English
LU publication?
yes
id
1d27b9ca-bdd8-4170-857e-850f2eb9c0c4
date added to LUP
2019-01-14 13:22:45
date last changed
2024-07-09 03:55:21
@article{1d27b9ca-bdd8-4170-857e-850f2eb9c0c4,
  abstract     = {{<p>ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the ‘HMG-box transcription factor 1’ (HBP1) through the PI<sub>3</sub>K-AKT–FOXO3a signaling axis. HBP1 inhibits both the transcriptional activating and repressing activity of MYCN, the latter being mediated through PRC2 activity. HBP1 itself is under negative control of MYCN through miR-17~92. Combined targeting of HBP1 by PI<sub>3</sub>K antagonists and MYCN signaling by BET- or HDAC-inhibitors blocks MYCN activity and significantly reduces tumor growth, suggesting a novel targeted therapy option for high-risk neuroblastoma.</p>}},
  author       = {{Claeys, Shana and Denecker, Geertrui and Durinck, Kaat and Decaesteker, Bieke and Mus, Liselot M. and Loontiens, Siebe and Vanhauwaert, Suzanne and Althoff, Kristina and Wigerup, Caroline and Bexell, Daniel and Dolman, Emmy and Henrich, Kai Oliver and Wehrmann, Lea and Westerhout, Ellen M. and Demoulin, Jean Baptiste and Kumps, Candy and Van Maerken, Tom and Laureys, Genevieve and Van Neste, Christophe and De Wilde, Bram and De Wever, Olivier and Westermann, Frank and Versteeg, Rogier and Molenaar, Jan J. and Påhlman, Sven and Schulte, Johannes H. and De Preter, Katleen and Speleman, Frank}},
  issn         = {{0950-9232}},
  language     = {{eng}},
  number       = {{15}},
  pages        = {{2690--2705}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Oncogene}},
  title        = {{ALK positively regulates MYCN activity through repression of HBP1 expression}},
  url          = {{http://dx.doi.org/10.1038/s41388-018-0595-3}},
  doi          = {{10.1038/s41388-018-0595-3}},
  volume       = {{38}},
  year         = {{2019}},
}